Patents by Inventor Janani KRISHNAMURTHY

Janani KRISHNAMURTHY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12086489
    Abstract: The present disclosure discloses methods and systems for managing multiple priority jobs at a multi-function device. The method includes receiving a first job at the multi-function device, wherein the first job is to be completed within a pre-defined time. Then, a second job is received at the multi-function device. Upon receiving the second job, a pre-defined algorithm is run to determine an execution order for the first job and the second job. Based on the pre-defined algorithm, either continue executing the first job or start executing the second job. This way, multiple jobs are managed at the multi-function device.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: September 10, 2024
    Assignee: Xerox Corporation
    Inventors: Janani Krishnamurthy, Surya Priyadharshini Selvam, Sridhar Ananthanarayanan
  • Publication number: 20240156929
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: September 12, 2023
    Publication date: May 16, 2024
    Inventors: Laurence J.N. COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • Publication number: 20240061630
    Abstract: The present disclosure discloses methods and systems for managing multiple priority jobs at a multi-function device. The method includes receiving a first job at the multi-function device, wherein the first job is to be completed within a pre-defined time. Then, a second job is received at the multi-function device. Upon receiving the second job, a pre-defined algorithm is run to determine an execution order for the first job and the second job. Based on the pre-defined algorithm, either continue executing the first job or start executing the second job. This way, multiple jobs are managed at the multi-function device.
    Type: Application
    Filed: August 22, 2022
    Publication date: February 22, 2024
    Applicant: XEROX CORPORATION
    Inventors: Janani Krishnamurthy, Surya Priyadharshini Selvam, Sridhar Ananthanarayanan
  • Patent number: 11786582
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: October 17, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J N Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • Publication number: 20220062396
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: April 6, 2021
    Publication date: March 3, 2022
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • Publication number: 20200085929
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: August 19, 2019
    Publication date: March 19, 2020
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • Publication number: 20170224798
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 10, 2017
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • Patent number: 9629877
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 25, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence JN Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • Publication number: 20160158285
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: May 14, 2014
    Publication date: June 9, 2016
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY